SLA archaeosomes combined with the TLR3 agonist Poly(I:C) comprise a powerful adjuvant system for SLP-based vaccines, inducing high levels of antigen-specific T cells that are functional and efficacious in a therapeutic tumor model. This evidence concerns the gene TLR3 and neoplasm.